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Abstract 
 
Background 
Nearly half patients with heart failure have normal left ventricular ejection fraction 
(LVEF), but their prognosis is no better than those with reduced LVEF. Although peak 
oxygen consumption (VO2) is an independent predictor of mortality in heart failure, it 
is unclear how cardiac function during exercise contributes to peak VO2. Therefore, we 
explored the useful parameters measured by exercise stress echocardiography to 
predict peak VO2 in patients with heart failure with preserved LVEF (HFpEF). 
Methods and results 
We assessed 80 patients being investigated for effort intolerance or dyspnea, and 
finally analyzed 50 patients who satisfied the HFpEF criteria. Mean peak VO2 was 
16.4 ± 2.8 ml/kg/min. Twenty-three patients (46.0%) achieved a peak VO2 <16.0 
ml/kg/min (Weber class C or D). There was a significant relationship between mitral 
systolic velocity (S’) and cardiac output (CO) at rest (R = 0.55, P < 0.0001) and peak 
exercise (R = 0.64, P <0.0001). The absolute increase in S’ from rest to peak exercise 
also correlated with the absolute increase in CO (R = 0.32, P = 0.02). Multivariate 
logistic regression analysis showed that S’ at peak exercise independently predicted 
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peak VO2. Receiver-operator characteristic curve analysis identified that an S’ at peak 
exercise of ≤8.13 cm/s predicted a peak VO2 <16.0 ml/kg/min (sensitivity 95.7%, 
specificity 44.4%, area under curve 0.70, 95% confidence interval 0.55–0.84, P = 0.004).  
Conclusions 
Mitral systolic velocity at peak exercise accurately reflects peak VO2, and may 
facilitate stratification of risk in patients with HFpEF. 
 
Key words: heart failure; exercise tolerance; exercise echocardiography; tissue Doppler 
echocardiography; mitral annular velocity.  
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Introduction 
 
Nearly half patients presenting with symptoms and signs of heart failure (HF) are 
reported to have normal left ventricular ejection fraction (LVEF), but mortality and 
morbidity are similar to those of patients with HF with reduced LVEF.1 The 
pathophysiology of HF with preserved LVEF (HFpEF) is characterized by diastolic 
dysfunction, impaired systolic function, aortic stiffening, abnormal ventricular-arterial 
coupling, chronotropic incompetence, and underlying diseases such as hypertension 
and diabetes mellitus.2-8 Patients with HFpEF most commonly complain of 
breathlessness during exercise. Exercise stress echocardiography (ESE) and 
cardiopulmonary exercise testing (CPET) have been used to demonstrate the 
pathophysiology of HFpEF.9-16 Peak oxygen consumption (VO2) on CPET is a 
well-established and independent predictor of mortality in patients with HF, including 
those with HFpEF,17-20 and there is reportedly a relationship between peak VO2 and 
parameters measured by rest echocardiography (RE) in patients with HFpEF.10,21 
Nevertheless, the relationship between peak VO2 and the parameters measured by 
ESE are not completely understood. We hypothesized that parameters measured by 
ESE would be more closely related to peak VO2 than those of RE, as peak VO2 reflects 
exercise tolerance. We performed a study to investigate the relationship between peak 
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VO2 and ESE parameters in patients with HFpEF, using ESE combined with CPET 
(ESE-CPET). 
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Methods 
 
Study population  
We enrolled patients with LVEF >50% who had been referred for investigation of effort 
intolerance or dyspnea. The diagnosis of HFpEF was made in those: with normal 
LVEF (>50%); who fulfilled the criteria for New York Heart Association functional 
class II or III; and had abnormal diastolic function (indeterminate or diastolic 
dysfunction)22 and/or a history of hospitalization for congestive heart failure (CHF). 
Hypertensive patients matched for age and sex without symptoms and signs of HF 
were also recruited as control in this study period. Exclusion criteria were significant 
aortic or mitral valve stenosis, congenital heart disease, infiltrative or hypertrophic 
obstructive cardiomyopathy, pericardial constriction, presence of a pacemaker or 
implantable cardiac defibrillator, chronic pulmonary disease requiring home oxygen 
therapy, severe renal dysfunction, uncontrolled hypertension despite medical therapy 
and an inability to exercise. Participants took their normal drugs on the day of 
ESE-CPET. The research protocol was approved by our institutional ethics committee. 
All patients provided written informed consent to participate. 
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Cardiopulmonary exercise testing and laboratory tests  
Patients performed ESE with concurrent ventilator expired gas analysis on a supine 
bicycle ergometer (Road, Echo Stress Table 750EC, Groningen, The Netherlands) 
capable of tilting to the left lateral position. Patients pedaled at a constant cadence 
(50 rotations/min), starting with an initial workload of 10 W for 3 minutes, which was 
then increased by 10 W/min (ramp protocol). During the test, the 12-lead 
electrocardiogram and heart rate were continuously monitored and blood pressure was 
measured every minute. The test was terminated if signs of severe distress or 
myocardial strain were observed, or if a patient reached their maximal level of 
physical exertion. We measured some parameters on a breath-by-breath basis using a 
gas analysis technique (MINATO 280S; Minato Ikagaku, Osaka, Japan). We also took 
a venous blood sample for routine laboratory analysis and measurement of serum 
N-terminal pro B-type natriuretic peptide (NT-proBNP) concentration. 
 
Rest and exercise stress echocardiography 
Two experienced clinicians performed RE and ESE using a Vivid E9 ultrasound system 
with a 2.5-MHz transducer (GE Vingmed Ultrasound, Horten, Norway). All imaging 
data were digitized and saved on an optical disc for off-line analysis (Echo Pac software 
version 112, GE Vingmed Ultrasound). All echocardiographic measurements were 
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taken according to the recommendations of the American Society of 
Echocardiography23 by an experienced sonographer without knowledge of the patients’ 
clinical status. All parameters were measured in triplicate and averaged. Rest 
standard 2-dimensional, M-mode and Doppler blood flow recordings were performed 
using standard methods.23 Peak early diastolic filling (E) and late diastolic filling (A) 
velocities and the E/A ratio were measured from transmitral flow. Tissue Doppler 
images of movement of the mitral annulus were obtained from the apical four-chamber 
view. A sample volume was placed at the septal and lateral annular sites. Analysis was 
performed for the early (E’) diastolic peak velocity and systolic (S’) peak velocity. The 
E/E’ ratio, E’ diastolic peak velocity and S’ peak velocity were calculated using the 
averaged values from the septal and lateral sites. The LV mass index and relative wall 
thickness were calculated by standard methods.23 Right atrial (RA) pressure was 
estimated by the inferior vena cava diameter and its response to inspiration.23  
Pulmonary artery systolic pressure (PASP) was estimated using the modified 
Bernoulli formula (4  [tricuspid regurgitation velocity (TRV) at end-expiration]2) + 
RA pressure.23 Exercise stress echocardiographic images were acquired at rest and 
peak stress. Analysis parameters were the E and A velocities, the E/A ratio, E’ diastolic 
peak velocity, S’ peak velocity, the E/E’ ratio and left ventricular out flow tract-velocity 
time integral (LVOT-VTI). Stroke volume (SV) was calculated by using the aortic valve 
Masada et al., page 
 
 
9
pulsed wave Doppler method, whereby LVOT-VTI was multiplied by the area of the 
aortic annulus. Cardiac output (CO) was calculated from the product of SV and heart 
rate (HR). Effective arterial elastance (Ea) was also calculated at rest and peak stress 
according to the following equation:8,24  
Ea = 0.9  systolic blood pressure / SV 
 
Statistical analysis 
Continuous variables are expressed as the mean ± standard deviation or number 
(proportion, %). Categorical variables were compared by use of Pearson’s chi-square 
test or Fisher exact test. Comparisons between patients with HFpEF and control 
subjects were performed using Student’s unpaired t-test. The paired t-test was used to 
compare rest and peak stress parameters. The repeated measures linear model 
analysis was used to define the within-group effect for each parameter over time, the 
between-group differences over time, and the time-by-group interactions. The 
relationship between S’ and CO during exercise was examined using the Pearson 
correlation coefficient. Multivariate linear regression was undertaken to assess 
independent correlations with peak VO2 using clinically relevant, significant variables 
from the univariate model. Receiver-operator characteristic (ROC) curves were plotted 
to determine the sensitivity and specificity of S’ at peak exercise and the E/E’ ratio at 
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rest, in order to predict peak VO2 <16.0 ml/kg/min. A P value <0.05 was considered to 
be statistically significant. Data were analyzed using JMP statistical software for 
Windows (version 12.0, SAS Institute Inc., Cary, NC, USA). 
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Results 
 
We assessed 80 consecutive patients: ultimately 57 were enrolled as they satisfied the 
criteria for HFpEF, and 7 were excluded either because of atrial fibrillation (n = 5) or 
because the echocardiographic images were not suitable for analysis (n = 2). Table 1 
provides a summary of the baseline demographic and clinical characteristics of the 50 
patients with HFpEF (40.0% were female, mean age 67 years ± 9 years) and 10 control 
subjects. Forty-five patients with HFpEF (90.0%) had hypertension, and 17 (34.0%) 
had ever been hospitalized for CHF. Furthermore, patients with HFpEF had higher log 
NT-proBNP serum levels (5.1 ± 1.3 vs 3.8 ± 0.8, P = 0.005), and were more likely to be 
taking beta-adrenoreceptor blockers (46.0% vs 10.0%, P = 0.03) than control subjects. 
 
Rest echocardiography 
The RE parameters are shown in Table 2. The RE parameters of patients with HFpEF 
having had larger or higher than control subjects were: left ventricular dimension in 
systole index (2.0 ± 0.3 vs 1.7 ± 0.2 cm/m2, P = 0.02), left atrial volume index (42.2 ± 
14.1 vs 27.1 ± 4.5 ml/m2, P = 0.002), LV mass index (97.0 ± 27.0 vs 73.1 ± 21.9 g/m2 , P = 
0.01), the E/E’ ratio (12.8 ± 3.2 vs 10.0 ± 1.7, P = 0.009), and PASP (19.1 ± 12.0 vs 8.7 ± 
9.3 mmHg, P = 0.01). 
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Exercise stress echocardiography combined with cardiopulmonary exercise testing 
The parameters measured by ESE-CPET are shown in Table 3. All parameters except 
for the E/A ratio in patients with HFpEF, as well as PASP and diastolic blood pressure 
in control subjects changed significantly from rest to peak exercise. Patients with 
HFpEF had lower S’ at peak (7.5 ± 1.4 vs 8.8 ± 0.9 cm/s, P = 0.007), higher the E/E’ 
ratio at rest (12.8 ± 3.2 vs 10.0 ± 1.7, P = 0.009), higher PASP at rest (19.1 ± 12.0 vs 8.7 
± 9.3 mmHg, P = 0.01) and peak (25.9 ± 19.1 vs 8.9 ± 12.1 mmHg, P = 0.02) , lower peak 
VO2 (16.4 ± 2.8 vs 18.4 ± 2.3 mmHg, P = 0.04), and lower respiratory exchange ratio 
(1.17 ± 0.12 vs 1.28 ± 0.10, P = 0.008) than control subjects. The ESE-CPET 
parameters which significantly differed as time-by-group interactions between the 
groups were: E wave (P = 0.002), S’ (P = 0.01), and VO2 (P = 0.03). Among the 
ESE-CPET parameters at peak exercise, A wave, E’, and PASP could not be measured 
in all patients (Table 3). Twenty-three (46.0%) patients with HFpEF achieved a peak 
VO2 <16.0 ml/kg/min (Weber class C or D).17,25 None of the patients developed chest 
pain, and no ST segment changes indicative of myocardial ischemia were observed in 
any patient during ESE-CPET. 
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Relationship between mitral systolic velocity and cardiac output  
The relationship between S’ and CO in patients with HFpEF is shown Figure 1; there 
was a significant relationship between S’ and CO at rest (R = 0.55, P < 0.0001) and 
peak exercise (R = 0.64, P <0.0001). The absolute increase in S’ from rest to peak 
exercise also correlated significantly with the absolute increase in CO (R = 0.32, P = 
0.02). 
 
Univariate and multivariate analyses for peak oxygen consumption 
The results of univariate and multivariate analyses to assess the relationships 
between peak VO2 and the variables measured by ESE-CPET in patients with HFpEF 
are shown in Table 4, 5. The ESE-CPET variables significantly related to peak VO2 on 
univariate analysis were: log NT-proBNP (R = -0.41, P = 0.004), S’ at rest (R = 0.40, P = 
0.004), S’ at peak exercise (R = 0.46, P = 0.0009), the E/E’ ratio at rest (R = -0.31, P = 
0.03), SV at rest (R = 0.29, P = 0.04), CO at peak exercise (R = 0.39, P = 0.008), and Ea 
at rest (R = -0.32, P = 0.02). There appeared to be strong relationships between S’ at 
rest and SV at rest (R = 0.57, P < 0.0001), and between S’ at peak exercise and CO at 
peak exercise (R = 0.64, P <0.0001), so we chose S’ at rest and peak exercise for the 
multivariate analysis. The multivariate regression analysis showed that S’ at peak 
exercise and the E/E’ ratio at rest were independent predictors of peak VO2. There was 
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a strong correlation between S’ at rest and S’ at peak exercise (R = 0.80, P <0.0001), so 
these parameters were not included in multivariate analysis together. According to the 
ROC curve analysis, a value of S’ at peak exercise ≤8.13 cm/s was the best predictor of 
a peak VO2 <16.0 ml/kg/min (sensitivity 95.7%, specificity 44.4%, area under curve 
[AUC] 0.70, 95% confidence interval [CI] 0.55–0.84, P = 0.004). The E/E’ ratio at rest 
was not a useful parameter (AUC 0.60; 95% CI 0.44–0.76, P = 0.26) (Figure 2). 
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Discussion 
 
To the best of our knowledge, ours is the first study to have investigated the 
relationship between peak VO2 and parameters measured by ESE in patients with 
HFpEF. Our major findings were that S’ at peak exercise and the E/E’ ratio at rest 
were independent predictors of peak VO2, and that S’ at peak exercise is a sensitive 
way of identifying patients with HFpEF impaired exercise capacity. Taking into 
account the strong relationship between peak VO2 and mortality, we recommend that 
measuring S’ at peak exercise should become a part of routine clinical practice. 
 
Mitral systolic velocity 
We found that S’ at peak exercise was an independent predictor of peak VO2 in 
patients with HFpEF. Peak VO2 is determined by three of the variables in the Fick 
equation thus:  
Peak VO2 = (SVpeak  HRpeak)  AVO2 
where AVO2 is the difference between arterial oxygen content and venous oxygen 
content. 
An impaired CO response in patients with HF correlates significantly with reductions 
in peak VO2,26 and CO is thought to be the chief determinant of VO2. We found that CO 
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at peak exercise correlated strongly with peak VO2. Cardiac output is the product of 
SV and HR. Kitzman et al.27 reported that SV augmentation during exercise was 
impaired in patients with HFpEF, and consequently HR increased to maintain CO and 
compensate for the inadequate SV response. Other non-invasive studies have also 
demonstrated similar hemodynamic responses to exercise in patients with 
HFpEF.9,11,12,16 Of the parameters measured by ESE that we found significantly 
correlated with peak VO2, S’ at peak exercise was most closely correlated with CO at 
peak exercise. Moreover, S’ at rest and the absolute increase in S’ from rest to peak 
exercise were also significantly correlated with CO at rest and the absolute increase in 
CO. We judge that S’ accurately reflects CO during exercise in patients with HFpEF. It 
has been reported that S’ is the accurate reflection of LV longitudinal systolic function 
that can be obtained with tissue Doppler imaging.5,28 Although it is recognized that 
there is a strong relationship between LV global longitudinal strain and peak VO2 in 
patients with HFpEF,10 it has not been clear how LV longitudinal systolic function 
during exercise contributes to CO response and peak VO2. Our findings demonstrate 
that LV longitudinal systolic function during exercise assessed by S’ significantly 
correlated with CO response, as SV augmentation combined with a HR response to 
maximize VO2. In our opinion, S’ at peak exercise is a valuable means of assessing 
exercise capacity in patients with HFpEF. 
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Mitral inflow to mitral relaxation velocity ratio 
The E/E’ ratio at rest was also an independent predictor of peak VO2. Previous reports 
have demonstrated the relationship between peak VO2 and the E/E’ ratio at rest.10,21 It 
has been reported that an elevated E/E’ ratio at rest correlated with an elevated mean 
pulmonary capillary wedge pressure and an elevated LV end diastolic pressure.22,29 
High resting filling pressure is associated with impaired exercise capacity.11 In our 
study, the E/E’ ratio at peak exercise did not correlate with peak VO2. None of the 
previous studies have examined the influence of the change in filling pressure brought 
about by exercise on exercise capacity. High LV filling pressure during exercise is 
frequently considered to be a cause of dyspnea, but conclusive evidence for this 
hypothesis remains elusive. Further studies are needed to clarify the relationship 
between LV filling pressure during exercise and exercise tolerance in patients with 
HFpEF. 
 
Impaired exercise capacity in patients with HFpEF 
Peak VO2 is recognized as a strong predictor of mortality in patients with HFpEF. 17-20 
Peak VO2 <16.0 ml/kg/min (Weber class C or D) reflects more severe HF and carries a 
worse prognosis.17,25 We found that S’ at peak exercise and the E/E’ ratio at rest were 
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independent predictors of peak VO2, but our ROC curve analysis revealed that S’ at 
peak exercise was the only sensitive means of identifying patients with HFpEF with 
peak VO2 <16.0 ml/kg/min. In our opinion, S’ at peak exercise is also a potentially 
valuable means of identifying patients with HFpEF at high risk of morbidity and 
mortality. 
 
Clinical implications 
Our study provides evidence that S’ during exercise is a useful parameter to reflect CO 
response and identify high risk patients with HFpEF impaired exercise capacity. 
The measurement of S’ at rest and during exercise was straightforward in all patients. 
In clinical practice, S’ is easier to measure than CO, even when the aortic valve pulsed 
wave Doppler method is used. If CPET equipment is not available, we recommend 
measuring S’ at peak exercise as a reflection of exercise capacity of patients with 
HFpEF. 
 
Limitations  
Our study had some limitations. First, our sample consisted of a small number of 
patients from a single center in Japan. Patients with HFpEF in our study had lower 
body surface area and body mass index (BMI) than those in previous reports. In 
Masada et al., page 
 
 
19 
general, the prevalence of obesity is lower in Asian populations than Westerners. 
Consistent with our results, BMI was relatively low in patients with HFpEF 
researched in Japan.30 Therefore, our results must be confirmed in a prospective study 
with a larger number of patients in other foreign countries. Second, all patients took 
their normal cardiac drugs on the day of ESE-CPET, as it was considered unethical to 
stop treatment entirely. Consequently, beta-adrenoreceptor blockers and calcium 
channel blockers may have influenced HR response. Third, among the ESE-CPET 
parameters at peak exercise, A wave, E’, and PASP could not be measured in all 
patients. A wave and E’ at peak exercise were not easy parameters to determine 
because of merging of E and A velocities, and E’ and the late diastolic peak velocity due 
to sinus tachycardia (ST). TRV at peak exercise was an also difficult parameter to 
determine due to ST and tachypnea. In our study, PASP at peak exercise in patients 
with HFpEF was the lowest feasible parameter of ESE-CPET. The reduced feasibility 
of parameters at peak exercise is one of the major limitations of ESE. It might have 
influenced our data. Finally, an S’ at peak exercise of ≤8.13 cm/s predicted a peak VO2 
<16.0 ml/kg/min with high sensitivity but low specificity. There was the potential for 
an increase of having false-positive cases, but it was suitable for screening of high risk 
patients with HFpEF because of high sensitivity. We think that S’ at peak exercise is a 
useful parameter in clinical practice to facilitate stratification of risk in patients with 
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HFpEF impaired exercise capacity.  
 
Conclusions 
Mitral systolic velocity at peak exercise accurately reflects peak VO2, and is a useful 
means of screening high risk patients with HFpEF impaired exercise capacity. 
Consideration should be given to measuring S’ at peak exercise in patients with 
HFpEF as a part of routine clinical exercise. 
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Figure legends 
 
Figure 1. Relationship between mitral systolic velocity (S’) and cardiac output (CO) at 
rest and peak exercise, and absolute increases from rest to peak exercise (Ǽ). 
 
Figure 2. Receiver-operating characteristic curve analysis using mitral systolic 
velocity (S’) at peak exercise and the mitral inflow to mitral relaxation velocity ratio 
(E/E’) at rest to identify patients with heart failure with preserved ejection fraction 
impaired peak oxygen consumption <16.0 ml/min/kg. Other abbreviations: AUC, area 
under the curve; CI, confidence interval. 
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Control P value
(n = 10)
68 ± 4 NS
4 (40) NS
1.70 ± 0.10 NS
24.1 ± 2.4 NS
䇲
䇲
10 (100) NS
3 (30) NS
6 (60) NS
0 (0) 0.04
14.3 ± 0.9 NS
1.0 ± 0.1 NS
6.3 ± 0.7 NS
61.0 ± 55.6 NS
3.8 ± 0.8 0.005
1 (10) 0.03
6 (60) NS
2 (20) NS
1 (10) NS
Values are presented as mean ± SD or n (%); BSA, body surface area; BMI, body mass index.
CHF, congestive heart failure; NYHA, New York Heart Association.
NT-proBNP, N-terminal pro-B-type-natriuretic peptide; ACE, angiotensin-converting enzyme.
ARA, angiotensin receptor antagonist.
20 (40)
1.67 ± 0.23
33 (66)
23.9 ± 4.6
Smoking, n (%) 29 (58)
Hypertension, n (%)
17 (34)
19 (38)
45 (90)
Creatinine, mg/dl
History of hospitalization for CHF 17 (34)
Hemoglobin, g/dl 13.2 ± 1.7
0.9 ± 0.3
Log NT-proBNP 
Medications, n (%)
Hemoglobin A1c, g/dl 6.0 ± 0.9
 ACE inhibitors/ARAs
5.1 ± 1.3 (n =49)
NT-proBNP, pg/ml 385.1 ± 644.3 (n =49)
 Calcium channel blockers
 Diuretic
23 (46)
34 (68)
12 (27)
18 (36)
 β-blockers
Table 1. Baseline Clinical Characteristics
Diabetes, n (%)
Valiables
Age, years
Females, (%)
BMI, kg/m2
NYHA class, n (%)
㻌䊡
HFpEF
(n = 50)
BSA, m2
67 ± 9
㻌䊢
 
 
 
 
 
 
 
 
 
 
 
 
 
Control P value
(n = 10)
2.1 ± 0.1 NS
3.5 ± 0.5 NS
0.9 ± 0.1 NS
0.9 ± 0.1 NS
2.7 ± 0.3 NS
1.7 ± 0.2 0.02
27.1 ± 4.5 0.002
0 (0) < 0.0001
42.6 ± 7.5 NS
15.6 ± 2.6 NS
63.2 ± 2.6 NS
73.1 ± 21.9 0.01
0 (0) 0.04
0.38 ± 0.04 NS
64.6 ± 12.6 NS
80.3 ± 9.3 NS
0.80 ± 0.11 NS
6.6 ± 1.0 NS
6.1 ± 1.1 NS
10.0 ± 1.7 0.009
0 (0) 0.02
19.4 ± 2.3 NS
8.7 ± 9.3 0.01
126.9 ± 26.6 NS
LAD, left arterial dimention; IVS, interventricular septum; PW, posterior wall.
LVDdI, left ventricular dimension in diastole index.
LVDsI, left ventricular dimension in systole index; LAVI, left atrial volume index.
LVEDVI, left ventricular end-diastolic volume index.
LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction.
LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index.
RWT, relative wall thickness; E wave, early mitral diastolic inflow velocity.
A wave, late mitral diastolic inflow velocity; E/A, early to late mitral inflow velocities ratio.
E', mitral relaxation velocity; S', mitral systolic velocity.
E/E', mitral inflow to mitral relaxation velocity ratio.
LVOT-VTI, left ventricular out flow tract-velocity time integral.
E', cm/s
S', cm/s
LVEDVI, ml/m2
Valiables
LAD, cm
IVS, cm
RWT
PW,cm
LVDdI, cm/m2
LVDsI, cm/m2
LAVI, ml/m2
Aortic annulus, cm
Table 2. Rest echocardiography
LVEF, %
LVMI, g/m2
PASP, pulmonary artery systolic pressure.
74.7 ± 16.1
0.39 ± 0.07
E wave, cm/s
A wave, cm/s
E/A 
5.6 ± 1.2
12.8 ± 3.2
20.7 ± 5.8
E/E' 
LVOT-VTI, cm
68.5 ± 19.2
1.21 ± 0.67
6.3 ± 1.7
 > 14.0, n (%) 19 (38)
129.1 ± 24.1PA acceleration time, ms
PASP, mmHg 19.1 ± 12.0
HFpEF
(n = 50)
2.0 ± 0.3
 > 34.0, n (%)
42.2 ± 14.1
2.0 ± 0.2
49.8 ± 13.4
19.4 ± 6.6
3.9 ± 0.6
0.9 ± 0.2
1.0 ± 0.2
3.0 ± 0.5
LVESVI, ml/m2
39 (78)
LV hypertrophy, n (%) 15 (30)
61.4 ± 4.8
97.0 ± 27.0
 
 
 
 
 
Table3. Exercise stress echocardiography combined with cardiopulmonary exercise testing
Within Control Within Between Time-Group
Group (n = 10) Group Groups Interaction
64.6 ± 12.6 NS
121.6 ± 16.9 NS
80.3 ± 9.3 NS
104.2 ± 20.3 (n = 7) NS
0.80 ± 0.11 NS
1.16 ± 0.36 (n = 7) NS
6.1 ± 1.1 NS
8.8 ± 0.9 0.007
6.6 ± 1.0 NS
9.3 ± 1.3 (n = 9) NS
10.0 ± 1.7 0.009
13.5 ± 2.0 (n = 9) NS
8.7 ± 9.3 0.01
8.9 ± 12.1 (n = 9) 0.02
19.4 ± 2.3 NS
23.0 ± 2.7 NS
66.2 ± 10.9 NS
79.2 ± 17.2 NS
4.6 ± 0.7 NS
9.8 ± 2.5 NS
3.6 ± 0.4 NS
18.4 ± 2.3 0.04
0 (0) 0.006
29.0 ± 3.2 NS
1.28 ± 0.10 0.008
113 ± 17 NS
176 ± 24 NS
65 ± 14 NS
71 ± 18 NS
70 ± 13 NS
124 ± 18 NS
81.4 ± 11.4 NS
7,978 ± 1,858 NS
22,039 ± 5,809 NS
1.6 ± 0.4 NS
2.1 ± 0.6 NS
MHR, maximum heart rate; Ea, effective arterial elastance.
VE/VCO2 ratio
RER ratio at peak
29.5 ± 5.2
1.17 ± 0.12
NS
%MHR at peak 77.8 ± 10.8
PASP, mmHg
 Rest
 Peak
19.1 ± 12.0
25.9 ± 19.1 (n = 34)
< 0.0001
< 0.0001
NS
0.03
NS
VO2, ml/kg/min
< 0.0001
20.7 ± 5.8
Diastolic blood pressure, mmHg
 Rest
176 ± 31
67 ± 15
Systolic blood pressure, mmHg
65.3 ± 17.9
75.3 ± 19.8
3.7 ± 0.6 Rest
 Peak 8.9 ± 2.6
Stroke volume, ml
NS
0.002
NS
NS
0.01
NS
NS
NS
NS
NS
NS
 Peak
Heart rate, bpm
73 ± 14
 Rest
 Peak
66 ± 10
Ea, mmHg/ml
NS
0.006
< 0.0001
118 ± 18
< 0.0001
Rate pressure product, mmHg x bpm
 Rest
 Peak
8,334 ± 1,893
20,789 ± 5,211
 Rest 1.9 ± 0.6
2.3 ± 0.7 Peak
12.8 ± 3.2
14.6 ± 5.3 (n = 45)
 Rest
 Peak
 Peak
 Rest 127 ± 21
 < 16.0, n (%) 23 (46)
16.4 ± 2.8 Peak
23.5 ± 4.7
LVOT-VTI, cm
 Rest
 Peak
Cardiac output, l/min
 Rest 4.3 ± 1.3
 Rest
 Peak
A wave, cm/s
 Rest
HFpEF
 Peak 91.8 ± 29.3 (n = 42)
68.5 ± 19.2
(n = 50)Valiables
E wave, cm/s
74.7 ± 16.1
109.5 ± 21.0
0.007
< 0.0001
< 0.0001
1.21 ± 0.67
1.32 ± 0.56 (n = 42)
S', cm/s
 Rest
 Peak
5.6 ± 1.2
7.5 ± 1.4
 Peak
E/A 
 Rest
E', cm/s
 Rest
 Peak
6.3 ± 1.7
8.2 ± 2.1 (n = 45)
E/E' 
 Rest
 Peak
VO2, oxygen consumption; VE/VCO2 ratio, ventilation to carbon dioxide output ratio; RER ratio, respiratory exchange ratio.
< 0.0001 < 0.0001
< 0.0001
< 0.0001
NS
< 0.0001
0.01
< 0.0001
< 0.0001
NS
< 0.0001
< 0.0001
0.007
< 0.0001
< 0.0001 NS
< 0.0001
< 0.0001
< 0.0001
0.005
0.03
< 0.0001
0.0002
 
R P value
-0.25 0.08
0.07 0.63
0.22 0.12
0.05 0.75
-0.41 0.004
-0.23 0.11
0.03 0.85
-0.02 0.87
0.15 0.32
-0.09 0.53
-0.004 0.98
0.04 0.78
0.25 0.11
-0.20 0.18
-0.24 0.14
0.40 0.004
0.46 0.0009
0.18 0.21
0.21 0.17
-0.05 0.74
-0.003 0.99
-0.31 0.03
-0.14 0.33
0.22 0.13
0.26 0.06
0.29 0.04
0.27 0.06
0.23 0.10
0.39 0.01
-0.05 0.70
0.17 0.23
0.21 0.14
0.24 0.10
-0.19 0.19
0.27 0.06
-0.32 0.02
-0.19 0.20
Systolic blood pressure at peak, mmHg
Diastolic blood pressure at rest, mmHg
Systolic blood pressure at rest, mmHg
Diastolic blood pressure at peak, mmHg
A wave at peak, cm/s
Creatinine, mg/dl
E/A at rest
Age, years
LAVI, ml/m2
E wave at peak, cm/s
A wave at rest, cm/s
Log NT-proBNP
Hemoglobin, g/dl
HFpEF (n = 50)
Table4. Univariate (R) of correlations between peak VO2 and the different variables
E wave at rest, cm/s
Univariate correlation
LVEF, %
LVMI, g/m2
Relation to Peak VO2
              in patients with HFpEF.
PA acceleration time, ms
Sex
E/A at peak
S' at rest, cm/s
S' at peak, cm/s
E' rest, cm/s
E' peak, cm/s
E/E' at rest
PASP at rest, mmHg
PASP at peak, mmHg
E/E' at peak
Stroke volume at rest, ml
Stroke volume at peak, ml
Cardiac output at rest, l/min
Cardiac output at peak, l/min
LVOT-VTI at rest, cm
LVOT-VTI at peak, cm
Ea at rest, mmHg/ml
Ea at peak, mmHg/ml
Heart rate at rest, bpm
Heart rate at peak, bpm
 
P value P value
0.27 0.15
0.45 0.79
0.30 0.23
0.14
0.04
0.04 0.07
0.71 0.63
β, beta regression coefficient; CI, confidence interval.
Multivariate regression Multivariate regression
β (95% CI) β (95%CI)
Ea at rest, mmHg/ml
Sex
S' at rest, cm/s
S' at peak, cm/s
E/E' at rest
Age, years
Log NT-proBNP
-0.27 (-0.52 to -0.02)
-0.23 (-1.45 to 1.00)
-0.06 (-0.14 to 0.02)
-0.21 (-1.78 to 1.37)
HFpEF (n = 50)
Table5. Multivariate (β) of correlations between peak VO2 and the different variables in patients
Relation to Peak VO2
             with HFpEF.
0.56 (-0.20 to 1.31)
-0.24 (-0.50 to 0.02)
-0.31 (-1.59 to 0.97)
-0.05 (-0.13 to 0.04)
-0.60 (-2.18 to 0.98)
0.62 (0.02 to 1.22)
-0.32 (-0.94 to 0.30) -0.39 (-1.03 to 0.26)
 
 
